Imatinib, an inhibitor of the Bcr-Abl tyrosine kinase, is approximately 95% bound to plasma
proteins, α1-acid glycoprotein (AGP) being the primary carrier. However, human serum …

Eight covalent tyrosine kinase inhibitors (TKIs) were investigated to determine the
characteristics of their covalent binding to plasma proteins. The data revealed that their …

The binding property between a ligand and its receptor is very important for numerous
biological processes. In this study, we developed a high epidermal growth factor receptor …

Purpose: The aim of the present study was to develop a simple and rapid reversed-phase
high performance liquid chromatographic method with UV detection for erlotinib …

The binding of drugs to plasma proteins determines its fate within the physiological system,
hence profound understanding of its interaction within the bloodstream is important to …

Entrectinib (ENB), a novel potent tyrosine kinase inhibitor, has demonstrated promising
activity against specific genetic alterations in various solid tumors. Investigating the …

In this study, we have investigated the binding affinity of the newly approved tyrosine kinase
inhibitor nintedanib (NIB) with human serum albumin under simulated physiological …

Activation of EGFR starts by ligand binding at the extracellular domain which results in homo
and heterodimerization, leading to phosphorylation, activation of downstream signaling …

Human serum albumin (HSA), the most abundant protein in plasma, is a monomeric
multidomain macromolecule that represents the main determinant of plasma oncotic …

Drug interaction with albumins significantly affects in vivo drug transport and biological
metabolism. To gain insight into the binding mechanisms of tyrosine-kinase inhibitor nilotinib …